Company Overview of Par Pharmaceutical Companies Inc.
Par Pharmaceutical Companies, Inc. develops, licenses, manufactures, markets, and distributes generic drugs in the United States. It operates through two segments, Par Pharmaceutical and Par Specialty Pharmaceuticals. The Par Pharmaceutical segment markets generic products under Par Pharmaceutical brand name and sterile products under the Par Sterile brand. This segment also offers dosage forms and delivery systems, including oral solids and alternate dosage forms, such as oral solids, injectables, topicals, nasal sprays, ophthalmics, films, and transdermal patches. In addition, this segment markets pharmaceutical products, including Exforge, Lovaza, Precedex, Lamictal XR, Luvox CR, and Foca...
One Ram Ridge Road
Chestnut Ridge, NY 10977
Founded in 1978
Key Executives for Par Pharmaceutical Companies Inc.
Chief Executive Officer and Director
Chief Financial Officer, Executive Vice President, Treasurer and Director
Senior Vice President and General Counsel of Generics
Chief Administrative Officer, General Counsel and Director
Compensation as of Fiscal Year 2017.
Par Pharmaceutical Companies Inc. Key Developments
Strides Shasun Limited Partners with Par Pharmaceutical to Market the Product in US
Sep 20 17
Strides Shasun Limited has partnered with Par Pharmaceutical to market product, Omega-3-Add Ethyl Esters Softgel capsules in the United States. The product to be manufactured in its facility in Bangalore will be launched immediately.
Par Pharmaceutical Receives U.S. FDA Approval of Ephedrine Sulfate Injection
Jan 30 17
Endo International plc announced that one of its operating companies, Par Pharmaceutical has received final approval from the U.S. Food and Drug Administration for its New Drug Application for ephedrine sulfate injection, a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings. Ephedrine sulfate for injection is packaged in cartons of twenty-five 50mg/mL, 1mL single use vials. Par expects to start shipping the product in February 2017.
Mylan, Allergan, Impax Laboratories, Lannett Co., Par Pharmaceuticals Companies, Sun Pharmaceutical Industries and West-Ward Pharmaceuticals Group Face Antitrust Lawsuit
Jun 23 16
Mylan NV and six other pharmaceutical companies are the targets of an antitrust lawsuit alleging that it illegally increased drug prices, including beefing up the price tags on doxycycline and digoxin. The plaintiff is the Rochester Drug Cooperative, a wholesale drug company based in Rochester, New York. The two drugs referenced in the suit are doxycycline, an antibiotic, and digoxin, a cardiac ailment treatment, which "exemplify this issue". Both drugs recently experienced a surge in pricing, doxycycline increasing 8,000% since October 2012, and digoxin increasing 800% since October 2013, according to the lawsuit. Other pharmaceutical companies named were Allergan, Impax Laboratories, Lannett Co., Par Pharmaceuticals Companies, Sun Pharmaceutical Industries and West-Ward Pharmaceuticals Group. Berger & Montague in Philadelphia, Faruqi & Faruqi in Jenkintown and Taus, Cebulash & Landau in New York City are representing the plaintiff.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|